Cargando…

Hsp90 inhibition sensitizes DLBCL cells to cisplatin

PURPOSE: Platinum-containing therapy is standard treatment for relapsed Diffuse Large B-Cell Lymphoma (DLBCL). However, the efficacy of treatment is limited by drug resistance leading to relapse. Cisplatin resistance has been linked to impairments of the DNA damage response, and several DNA repair p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Linnéa, Issa, Issa Ismail, Haraldsdóttir, Hulda, Hald, Jonas Laugård, Schmitz, Alexander, Due, Hanne, Dybkær, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956557/ https://www.ncbi.nlm.nih.gov/pubmed/35190872 http://dx.doi.org/10.1007/s00280-022-04407-5

Ejemplares similares

A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma
por: Issa, Issa Ismail, et al.
Publicado: (2021)

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
por: Rodrigues Moita, Ana J., et al.
Publicado: (2020)

Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2020)

HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells
por: Ewers, Katharina M., et al.
Publicado: (2021)

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors
por: Woodford, Mark R., et al.
Publicado: (2016)

Targeting HSF1 sensitizes cancer cells to HSP90 inhibition
por: Chen, Yaoyu, et al.
Publicado: (2013)

Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016)

Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
por: Park, Sangkyu, et al.
Publicado: (2019)

Circulating heat shock protein 90 (Hsp90) and autoantibodies to Hsp90 are increased in patients with atopic dermatitis
por: Sitko, Krzysztof, et al.
Publicado: (2021)

MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index
por: Due, Hanne, et al.
Publicado: (2020)

Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade
por: Liu, Jiao, et al.
Publicado: (2022)

Identification of Conserved Moieties in Metabolic Networks by Graph Theoretical Analysis of Atom Transition Networks
por: Haraldsdóttir, Hulda S., et al.
Publicado: (2016)

C0818, a novel curcumin derivative, interacts with Hsp90 and inhibits Hsp90 ATPase activity
por: Fan, Yingjuan, et al.
Publicado: (2017)

Senescence-related gene c-Myc affects bladder cancer cell senescence by interacting with HSP90B1 to regulate cisplatin sensitivity
por: Wang, Yaxuan, et al.
Publicado: (2023)

Hsp-90 and the biology of nematodes
por: Him, Nik AIIN, et al.
Publicado: (2009)

Mechanisms of Hsp90 regulation
por: Prodromou, Chrisostomos
Publicado: (2016)

Regulatory Mechanisms of Hsp90
por: Prodromou, Chrisostomos
Publicado: (2017)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Role of HSP90 in Cancer
por: Birbo, Bereket, et al.
Publicado: (2021)

Organismal Roles of Hsp90
por: van Oosten-Hawle, Patricija
Publicado: (2023)

HSP90AB1 as the Druggable Target of Maggot Extract Reverses Cisplatin Resistance in Ovarian Cancer
por: Wang, Daojuan, et al.
Publicado: (2023)

The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep
por: Chang, Cheng, et al.
Publicado: (2023)

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
por: Usmani, Saad Z, et al.
Publicado: (2010)

Blocking the survival of the nastiest by HSP90 inhibition
por: Workman, Paul, et al.
Publicado: (2016)

Hsp90: a specialized but essential protein-folding tool
por: Young, Jason C., et al.
Publicado: (2001)

Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review
por: Madsen, Marie Lindhard, et al.
Publicado: (2019)

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
por: Kijima, Toshiki, et al.
Publicado: (2018)

The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases
por: Lackie, Rachel E., et al.
Publicado: (2017)

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery
por: Li, Ting, et al.
Publicado: (2018)

Hsp40s Specify Functions of Hsp104 and Hsp90 Protein Chaperone Machines
por: Reidy, Michael, et al.
Publicado: (2014)

USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer
por: Kosinsky, Robyn Laura, et al.
Publicado: (2019)

Control of Canalization and Evolvability by Hsp90
por: Milton, Claire C., et al.
Publicado: (2006)

Targeting HSP90 for cancer therapy
por: Mahalingam, D, et al.
Publicado: (2009)

Hsp90 depletion goes wild
por: Siegal, Mark L, et al.
Publicado: (2012)

The ‘active life’ of Hsp90 complexes()
por: Prodromou, Chrisostomos
Publicado: (2012)

Hsp90, the Concertmaster: Tuning Transcription
por: Khurana, Nidhi, et al.
Publicado: (2015)

Hsp90 Promotes Kinase Evolution
por: Lachowiec, Jennifer, et al.
Publicado: (2015)

Targeting Hsp90 in urothelial carcinoma
por: Chehab, Mahmoud, et al.
Publicado: (2015)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

Distinct Roles of Molecular Chaperones HSP90α and HSP90β in the Biogenesis of KCNQ4 Channels
por: Gao, Yanhong, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nutj7p2g95a0h74as43neatoj2